Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDV-01 Versus Observation in Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT07313891Phase 3Withdrawn
- Sponsor
- Relmada Therapeutics, Inc.
- Start
- May 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of NDV-01 in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Relmada Therapeutics, Inc. Primary endpoint: Disease-Free Survival at 2 years. Planned start May 2026; status: withdrawn.
02
Drugs
NDV-01
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07313891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313891.